Relay Therapeutics (NASDAQ:RLAY) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Relay Therapeutics (RLAY): Revisiting Valuation After a Sharp Rebound in 2024 [Yahoo! Finance]
Will Broad Zovegalisib Breast Cancer Data Reshape Relay Therapeutics' (RLAY) Targeted Oncology Narrative? [Yahoo! Finance]
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 [Yahoo! Finance]
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025